Loading
A phase 2 trial of Carboplatin, Gemcitabine and Eribulin in triple-negative breast cancer, run by BioNTech SE, active and no longer recruiting.
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy is a phase 2 interventional study registered as NCT06449222 by BioNTech SE, with 83 participants enrolled, started 2024-08-26 and due to reach its primary completion in 2028-08. Interventions recorded: BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel, Carboplatin, Gemcitabine and Paclitaxel.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Eribulin, BioNTech, Bristol Myers Squibb, Gemcitabine and the tag pipeline.
Shares Eribulin, Carboplatin, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Bristol Myers Squibb, Gemcitabine, Carboplatin and the tag pipeline.
Shares Eribulin, Gemcitabine and the tag pipeline.
Shares BioNTech, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares BioNTech, Bristol Myers Squibb and the tag pipeline.
Shares Eribulin, Gemcitabine and the tag pipeline.
Shares Gemcitabine, Triple-negative breast cancer (TNBC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/